On Feb. 7, AstraZeneca announced it received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on ...

Soriot discussed the impact of potential tariffs during a call on AstraZeneca's earnings. For the three months ended March 31, during which period the firm netted $13.59 billion in total revenue, an ...

Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

Despite AstraZeneca’s falling share price today, this writer believes the London-listed pharmaceutical giant could be worth a ...

AstraZeneca said today it may face a fine of up to $8m over suspected unpaid import taxes in China as the drugmaker works to ...

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...

AstraZeneca’s AZN first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.10. Core earnings of $2.49 per share rose 21% year over year on ...